In the REGARDS cohort, low hs-CRP levels were associated with a reduced risk of stroke, and CHD morbidity and mortality, while low LDL-c was not associated with protective effects.
In patients with a systolic BP between 120 and <140 mmHg, a diastolic BP between 70 and <80 mmHg was associated with a lower risk of adverse outcomes as compared to lower and higher DBP.
ESC 2018 Cilie van 't Klooster asks Prof. Ridker how the results on canakinumab from the CANTOS trial can be implemented in clinical practice and which challenges are left?
Dapagliflozin met the primary safety endpoint of non-inferiority for MACE and showed a significant reduction in the hospitalization for HF or CV death primary efficacy endpoint in DECLARE-TIMI 58.
Professor Erik Stroes gives an overview of evidence that inflammation plays a role in CVD and diabetes and considers options to target the hyperactive inflammatory state to lower residual CV risk.
Prof. Jennifer Robinson illustrates the importance of baseline LDL-c levels in CV risk reduction with PCSK9 inhibitors and explains which patients should get this treatment.
In recent years, new insights into the CV risk associated with diabetes have resulted in a new management approach of T2DM. Prof. Deanfield explains the rationale of a multifactorial approach.
Prof. Ference shows that PCSK9 inhibition has biologically and therapeutically equivalent effects on the risk of CVD as observed with statins.
ELISA-based measurement of apolipoprotein C-III on individual lipoproteins did not provide additional predictive information on development of coronary artery disease.
Continuous direct factor Xa inhibitor therapy with apixaban was a safe and effective anticoagulation alternative in patients at risk of stroke undergoing atrial fibrillation catheter ablation.
The new guidelines on management of CVD during pregnancy consider new evidence on diagnostic techniques, risk assessment and drug therapy that became available since the 2012 edition.
ESC 2018 The benefit of sacubitril/valsartan in HFrEF is not subject to debate, but opinions do vary on when to use it. An impression of the arguments on whether or not it should be the starting treatment.